Clone 14 is recommended for: the detection of immunoregulatory T cell subset imbalances in autoimmune disorders and immunodeficiency states, categorisation of T cell acute lymphoblastic leukaemia and lymphoblastic lymphoma in conjunction with other antigens and determination of CD4/CD8 ratios in immune deficiencies, rheumatoid arthritis and multiple sclerosis.
| Inventor | Institute |
|---|---|
| Nancy Hogg | Cancer Research UK, London Research Institute: Lincoln's Inn Fields |
| Cat. #: | 151035 |
|---|---|
| Tool sub type: | Primary antibody |
| Unit size: | 100 ug |
| Research Fields: | Cancer;Immunology;Stem cell biology |
| Application: | ELISA ; FACS ; IHC ; IP |
| Target: | CD8 |
| Reactivity: | Human |
| Clone: | 14 |
| Host: | Mouse |
| Class: | Monoclonal |
| Alternate name: | Leu2 |
|---|---|
| Product description: | Clone 14 is recommended for: the detection of immunoregulatory T cell subset imbalances in autoimmune disorders and immunodeficiency states, categorisation of T cell acute lymphoblastic leukaemia and lymphoblastic lymphoma in conjunction with other antigens and determination of CD4/CD8 ratios in immune deficiencies, rheumatoid arthritis and multiple sclerosis. |
| Conjugation: | Unconjugated |
| Isotype: | IgG1 |
| Immunogen: | Fibronectin-purified human monocytes |
| Myeloma used: | Sp2/0-Ag14 |
| Target background: | CD8 is a T cell co-receptor that recognises, together with the T cell receptor, MHC class I molecules. CD8 is present on human suppressor / cytotoxic T cells, 30% of circulating T cells. Clone 14 is recommended for: the detection of immunoregulatory T cell subset imbalances in autoimmune disorders and immunodeficiency states, categorisation of T cell acute lymphoblastic leukaemia and lymphoblastic lymphoma in conjunction with other antigens and determination of CD4/CD8 ratios in immune deficiencies, rheumatoid arthritis and multiple sclerosis. |
|---|
| Format: | Liquid |
|---|---|
| Concentration: | 1 mg/ml |
| Storage buffer: | PBS with 0.02% azide |
| Storage conditions: | -15° C to -25° C |
| Shipping conditions: | Dry ice |
| References: |
Hogg et al. 1999. J Clin Invest. 103(1):97-106. PMID: 9884339. |
|---|
| Cat. # | Tool Name | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 151016 | Anti-CyclinA [E72.1] |
Key Info
Anti-CyclinA [E72.1]
|
View Tool | |||||||||||||||||||
| 151021 | Anti-CyclinB1 [V152] |
Key Info
Anti-CyclinB1 [V152]
|
View Tool | |||||||||||||||||||
| 151022 | Anti-IL12 [1-1A4] |
Key Info
Anti-IL12 [1-1A4]
|
View Tool | |||||||||||||||||||
| 151029 | Anti-HSVICP8 [11E2] |
Key Info
Anti-HSVICP8 [11E2]
|
View Tool | |||||||||||||||||||
| 151020 | Anti-CyclinB1 [V143.1] |
Key Info
Anti-CyclinB1 [V143.1]
|
View Tool | |||||||||||||||||||
Please note we may take up to three days to respond to your enquiry.
CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.